CO2020013679A2 - Formulaciones farmacéuticas mejoradas - Google Patents
Formulaciones farmacéuticas mejoradasInfo
- Publication number
- CO2020013679A2 CO2020013679A2 CONC2020/0013679A CO2020013679A CO2020013679A2 CO 2020013679 A2 CO2020013679 A2 CO 2020013679A2 CO 2020013679 A CO2020013679 A CO 2020013679A CO 2020013679 A2 CO2020013679 A2 CO 2020013679A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical formulations
- formulation
- improved pharmaceutical
- combination
- sorbitol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN La presente invención proporciona una formulación farmacéutica sólida fluida que comprende uno o más principios activos y una combinación que comprende sorbitol y parafina líquida, un envase que contiene la formulación, un procedimiento para la fabricación de la formulación y el uso de la combinación en la formulación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201811016594 | 2018-05-02 | ||
PCT/EP2019/060605 WO2019211159A1 (en) | 2018-05-02 | 2019-04-25 | Improved pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020013679A2 true CO2020013679A2 (es) | 2021-03-19 |
Family
ID=66290450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0013679A CO2020013679A2 (es) | 2018-05-02 | 2020-10-30 | Formulaciones farmacéuticas mejoradas |
Country Status (14)
Country | Link |
---|---|
US (2) | US11648201B2 (es) |
EP (1) | EP3787596A1 (es) |
JP (1) | JP2021522299A (es) |
KR (1) | KR20210005224A (es) |
CN (1) | CN112040929A (es) |
BR (1) | BR112020021852A2 (es) |
CA (1) | CA3099055A1 (es) |
CL (1) | CL2020002766A1 (es) |
CO (1) | CO2020013679A2 (es) |
MX (2) | MX2020011541A (es) |
PH (1) | PH12020551798A1 (es) |
SG (1) | SG11202010792TA (es) |
TW (1) | TW202002953A (es) |
WO (1) | WO2019211159A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3174693A1 (en) * | 2020-05-08 | 2021-11-11 | Fertin Pharma A/S | Flowpack for oral delivery of active ingredients |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2716624B1 (fr) * | 1994-02-25 | 1996-05-03 | Jouveinal Lab | Gelée laxative hypocalorique à base d'huile de paraffine liquide et de lactulose, son procédé de préparation. |
ITFI970184A1 (it) | 1997-07-30 | 1999-01-30 | Menarini Farma Ind | Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico |
RU2175554C2 (ru) | 1999-03-30 | 2001-11-10 | Пермское научно-производственное объединение "Биомед" | Оральный препарат интерферона в виде таблеток |
CZ300615B6 (cs) * | 1999-11-30 | 2009-07-01 | Panacea Biotec Limited | Rychle rozpustný farmaceutický prostredek v pevné dávkové forme s prodlouženou sladkou chutí a zpusob jeho prípravy |
US20100129310A1 (en) | 2004-08-09 | 2010-05-27 | Pavak Rajnikanth Mehta | Stabilized desloratadine composition |
DE102005009240A1 (de) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
AU2006226887A1 (en) * | 2005-03-23 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate corticosteroid and antihistamine formulations |
US7611739B2 (en) * | 2006-01-06 | 2009-11-03 | Amerilab Technologies, Inc. | Method of using guava extract and composition including guava extract |
US20090004270A1 (en) | 2006-01-06 | 2009-01-01 | Amerilab Technologies, Inc. | Method of using guava extract |
EP1970053A1 (en) | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
EP2240174A1 (en) * | 2008-02-13 | 2010-10-20 | Ratiopharm GmbH | Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide |
RU2497503C9 (ru) * | 2008-03-10 | 2014-09-20 | Байер Конзюмер Кер АГ | Приятная на вкус твердая композиция, включающая нейтрализатор кислотности и стимулятор слюноотделения |
CN102046202A (zh) * | 2008-03-26 | 2011-05-04 | 塔罗制药北美有限公司 | 用于口服药剂的稳定脂质组合物 |
TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
RU2454221C2 (ru) | 2010-07-06 | 2012-06-27 | Общество с ограниченной ответственностью "Завод Медсинтез" | Способ получения лиофилизированного противовирусного средства |
EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
JP5600747B2 (ja) | 2011-01-17 | 2014-10-01 | 武田薬品工業株式会社 | 口腔内分散性製剤 |
WO2013077829A1 (en) | 2011-11-21 | 2013-05-30 | Mahmut Bilgic | Water-soluble pharmaceutical granules |
AU2013263292B2 (en) * | 2012-05-16 | 2018-03-08 | Maninder SANDHU | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
EA201592236A1 (ru) | 2013-06-04 | 2016-06-30 | Вайом Байосайнсиз Пвт. Лтд. | Частицы с нанесенным покрытием и композиции, включающие такие частицы |
-
2019
- 2019-04-25 EP EP19719868.2A patent/EP3787596A1/en active Pending
- 2019-04-25 WO PCT/EP2019/060605 patent/WO2019211159A1/en unknown
- 2019-04-25 MX MX2020011541A patent/MX2020011541A/es unknown
- 2019-04-25 BR BR112020021852-9A patent/BR112020021852A2/pt unknown
- 2019-04-25 CA CA3099055A patent/CA3099055A1/en active Pending
- 2019-04-25 JP JP2020561663A patent/JP2021522299A/ja active Pending
- 2019-04-25 US US17/051,732 patent/US11648201B2/en active Active
- 2019-04-25 CN CN201980028696.XA patent/CN112040929A/zh active Pending
- 2019-04-25 SG SG11202010792TA patent/SG11202010792TA/en unknown
- 2019-04-25 KR KR1020207034567A patent/KR20210005224A/ko unknown
- 2019-04-30 TW TW108115070A patent/TW202002953A/zh unknown
-
2020
- 2020-10-26 CL CL2020002766A patent/CL2020002766A1/es unknown
- 2020-10-28 PH PH12020551798A patent/PH12020551798A1/en unknown
- 2020-10-29 MX MX2023008569A patent/MX2023008569A/es unknown
- 2020-10-30 CO CONC2020/0013679A patent/CO2020013679A2/es unknown
-
2023
- 2023-03-30 US US18/128,922 patent/US20230346704A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202010792TA (en) | 2020-11-27 |
US20210236426A1 (en) | 2021-08-05 |
JP2021522299A (ja) | 2021-08-30 |
EP3787596A1 (en) | 2021-03-10 |
US20230346704A1 (en) | 2023-11-02 |
BR112020021852A2 (pt) | 2021-02-23 |
MX2023008569A (es) | 2023-08-08 |
PH12020551798A1 (en) | 2021-06-14 |
KR20210005224A (ko) | 2021-01-13 |
US11648201B2 (en) | 2023-05-16 |
CN112040929A (zh) | 2020-12-04 |
CL2020002766A1 (es) | 2021-02-19 |
WO2019211159A1 (en) | 2019-11-07 |
TW202002953A (zh) | 2020-01-16 |
CA3099055A1 (en) | 2019-11-07 |
MX2020011541A (es) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
SV2017005426A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
IL279034A (en) | Pharmaceutical combination, composition and formulation containing a glucokinase activator and an alpha-glucosidase inhibitor, preparation methods and uses thereof | |
MX2020003661A (es) | Formas de dosificacion de liquidos, metodos de fabricacion y uso. | |
CL2021000741A1 (es) | Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
AR104482A1 (es) | Sistema de suministro de multi cámara | |
BR112016022340A2 (pt) | Composição, uso cosmético de uma composição, medicamento e kit | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
UY36898A (es) | Variantes de hppd y métodos de uso | |
CL2017002214A1 (es) | Formulación de combinación de tesofensina y betabloqueante | |
CL2018001590A1 (es) | Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina. | |
CL2018003418A1 (es) | Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo. | |
CO2020013679A2 (es) | Formulaciones farmacéuticas mejoradas | |
SV2019005811A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
UY37261A (es) | Formulación combinada de tres compuestos antivirales | |
CO2017001076A2 (es) | Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam | |
CL2020000136A1 (es) | Composiciones que contienen darunavir, cobicistat, emtricitabina y tenofovir alafenamida para uso en tratamiento de vih. | |
CL2018002577A1 (es) | Forma física de un modulador sgr | |
AR107986A1 (es) | Solubilización mejorada a través del uso de una combinación de surfactantes de cadena extendida | |
BR112018070603A2 (pt) | formulações líquidas de fosfaplatina | |
BR112018010616A2 (pt) | compostos inibidores seletivos de mmp-12 | |
EA201991594A1 (ru) | Депо-препарат | |
CL2014001492A1 (es) | Formulacion biocida capaz de impedir la proliferacion de microorgamismos en superficies |